Akebia Therapeutics specializes in developing and marketing medicines for patients with kidney-related disorders. Its flagship product in Phase III development is vadadustat, an oral therapy that treats anemia due to chronic kidney disease in adult patients. In addition, the company has collaboration agreements with Otsuka Pharmaceutical and Mitsubishi Tanabe Pharma for the development and commercialization of vadadustat in various countries.